Study Details

Back to Search Results

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01007292

Astellas Study ID

The unique identification code given by the study sponsor.

155-CL-031

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Lymphoma

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Nov 2009 - Jun 2015

Masking

None (Open Label)

Enrollment number

43

A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site US810 University of Alabama at Birmingham

Birmingham, United States, 35294-3300

Site US1895 Tower Cancer Research Foundation

Beverly Hills, United States, 90211-1850

Site US46 Washington Cancer Institute (MedStar Research Institute)

Washington DC, United States, 20010

Site US2815 American Clinical Trials

Pembroke Pines, United States, 33028

Site US2778 John B. Amos Cancer Center

Columbus, United States, 31904

Site US50 Rush University Medical Center

Chicago, United States, 60612

Site US55 Loyola University Hospital - Maywood

Maywood, United States, 60153

Site US419 Louisiana State University School of Medicine

Shreveport, United States, 71103

Site US516 National Cancer Institute

Bethesda, United States, 20892-1457

Site US667 Washington University School of Medicine

St. Louis, United States, 63110

Site US9 Mount Sinai School of Medicine

New York, United States, 10029

Site US2802 Mecklenburg Medical Group

Charlotte, United States, 28204

Site US2149 Gabrail Cancer Center Research

Canton, United States, 44718

Site US1996 Providence Portland Medical Center

Portland, United States, 97213

Site US960 Fox Chase Cancer Center

Philadelphia, United States, 19111

Site US58 Medical Center for the University of South Carolina

Charleston, United States, 29425

Site US402 University of Texas Health Science Center - San Antonio

San Antonio, United States, 78229

Site FR2701 CH de Blois

Blois, France, 41150

Site FR1926 Institut Bergonie

Bordeaux-cedex, France, 33076

Site FR2625 Centre Hospitalier de Cannes

Cannes, France, 6400

Site FR2814 CHU Nantes Service hématologie Clinique

Nantes, France, 44093

Site FR1896 CHU Nice

Nice, France, 6200

Site FR2700 Centre Antoine Lacassagne

Nice, France, 06189

Site FR476 Hopital Saint Louis

Paris, France, 75475

Site FR1920 CHU de Poitiers

Poitiers, France, 86021

Site FR1889 Centre de Lutte Contre le Cancer - Centre Henri Becquerel

Rouen, France, 76038

Site FR1897 Hopital Bretonneau

Tours, France, 37044

Site FR2571 Hopitaux de Brabois

Vandoeuvre, France, 54550

Site ES1349 Hospital del Mar

Barcelona, Spain, 08003

Site ES1339 Hospital Universitario Ramon y Cajal

Madrid, Spain, 28034

Site ES1350 Hospital Universitario de la Princesa

Madrid, Spain, 28006

Site ES1346 Hospital Universitario de Salamanca

Salamanca, Spain, 37007

Site GB2702 Addenbrookes Hospital

Cambridge, United Kingdom, CB2 0QQ

Site GB1928 St. Georges Hospital

London, United Kingdom, SW17 0QT

Site GB2624 The Christie NHS Foundation Trust

Manchester, United Kingdom, M20 4BX

Site GB2012 Nottingham City Hospital

Nottingham, United Kingdom, NG5 1PB

Site GB1903 Oxford Radcliffe Hospital

Oxford, United Kingdom, OX3 7LJ

Site ES1344 Hospital Universitario Vall D'Hebron

Barcelona, Spain, 08035

Site ES2967 Hosptial Universitario Madrid Sanchinarro

Madrid, Spain, 28050

Site US2879 Yale University School of Medicine

New Haven, United States, 06520

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo